Tadalafil + Sildenafil Citrate
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Erectile Dysfunction
Conditions
Erectile Dysfunction
Trial Timeline
May 1, 2010 → Jun 1, 2011
NCT ID
NCT01122264About Tadalafil + Sildenafil Citrate
Tadalafil + Sildenafil Citrate is a approved stage product being developed by Eli Lilly for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT01122264. Target conditions include Erectile Dysfunction.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01122264 | Approved | Completed |
Competing Products
20 competing products in Erectile Dysfunction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| tadalafil + placebo | Eli Lilly | Phase 3 | 77 |
| YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo | Yuhan | Phase 2 | 52 |
| Tacrolimus + Placebo | Astellas Pharma | Approved | 85 |
| Mirabegron | Astellas Pharma | Phase 1/2 | 41 |
| LY2452473 + Tadalafil + LY900010 | Eli Lilly | Phase 1 | 33 |
| tadalafil + placebo | Eli Lilly | Phase 3 | 77 |
| tadalafil | Eli Lilly | Phase 3 | 77 |
| LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473) | Eli Lilly | Phase 2 | 52 |
| Tadalafil | Eli Lilly | Approved | 85 |
| tadalafil + placebo | Eli Lilly | Approved | 85 |
| Tadalafil + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + Tadalafil | Eli Lilly | Approved | 85 |
| Tadalafil + Placebo | Eli Lilly | Approved | 85 |
| tadalafil | Eli Lilly | Approved | 85 |
| Tadalafil + Sildenafil | Eli Lilly | Approved | 85 |
| tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)] | Eli Lilly | Phase 3 | 77 |
| Tadalafil + Placebo | Eli Lilly | Approved | 85 |
| Dapoxetine | Johnson & Johnson | Phase 3 | 77 |
| dapoxetine | Johnson & Johnson | Phase 3 | 77 |
| Placebo + Dapoxetine + PDE5I (phosphodiesterase-5 inhibitor) | Johnson & Johnson | Phase 3 | 77 |